Ellerson Group Inc. ADV Cuts Position in DexCom, Inc. $DXCM

Ellerson Group Inc. ADV trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 22.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 53,403 shares of the medical device company’s stock after selling 15,044 shares during the quarter. DexCom comprises 2.4% of Ellerson Group Inc. ADV’s investment portfolio, making the stock its 19th biggest position. Ellerson Group Inc. ADV’s holdings in DexCom were worth $3,544,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of DXCM. Brighton Jones LLC raised its holdings in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the period. Integrated Wealth Concepts LLC raised its holdings in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC raised its holdings in shares of DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth raised its holdings in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after buying an additional 841 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in shares of DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after buying an additional 258 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on DXCM shares. TD Cowen dropped their target price on DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, May 1st. William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. Robert W. Baird set a $80.00 target price on DexCom in a report on Friday, May 1st. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Finally, Mizuho set a $75.00 price objective on DexCom in a report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $82.21.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,112 shares of company stock worth $379,990 over the last 90 days. 0.28% of the stock is currently owned by company insiders.

DexCom Price Performance

DXCM stock opened at $72.10 on Tuesday. The stock’s 50 day moving average is $63.72 and its two-hundred day moving average is $66.09. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a market capitalization of $27.82 billion, a PE ratio of 30.81, a P/E/G ratio of 1.19 and a beta of 1.40. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the business posted $0.32 EPS. DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. Analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.